PE20250453A1 - Piridazinonas y sus metodos de uso - Google Patents

Piridazinonas y sus metodos de uso

Info

Publication number
PE20250453A1
PE20250453A1 PE2024003155A PE2024003155A PE20250453A1 PE 20250453 A1 PE20250453 A1 PE 20250453A1 PE 2024003155 A PE2024003155 A PE 2024003155A PE 2024003155 A PE2024003155 A PE 2024003155A PE 20250453 A1 PE20250453 A1 PE 20250453A1
Authority
PE
Peru
Prior art keywords
compound
prodrug
pharmaceutically acceptable
pyridazinones
methods
Prior art date
Application number
PE2024003155A
Other languages
English (en)
Inventor
Mark W Ledeboer
Matthew H Daniels
Maolin Yu
Jean-Christophe P Harmange
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of PE20250453A1 publication Critical patent/PE20250453A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona un procedimiento para preparar el Compuesto 100. Este procedimiento comprende el hacer reaccionar el Compuesto 100-3 con el Compuesto 100-2 para producir el Compuesto 100-1 en presencia de N,N-diisopropiletilamina (DIEA). Posteriormente, se desprotege el Compuesto 100-1 con acido trifluoroacetico (TFA) en presencia de diclorometano (DCM) para producir el Compuesto 100. Tambien se reivindica el profarmaco del Compuesto 100 o una sal farmaceuticamente aceptable del mismo, y una composicion farmaceutica que comprende dicho profarmaco y un vehiculo farmaceuticamente aceptable.
PE2024003155A 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso PE20250453A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862732728P 2018-09-18 2018-09-18
US201862780553P 2018-12-17 2018-12-17
PCT/US2019/051680 WO2020061162A1 (en) 2018-09-18 2019-09-18 Pyridazinones and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20250453A1 true PE20250453A1 (es) 2025-02-19

Family

ID=69887813

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2021000320A PE20211774A1 (es) 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso
PE2024003155A PE20250453A1 (es) 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2021000320A PE20211774A1 (es) 2018-09-18 2019-09-18 Piridazinonas y sus metodos de uso

Country Status (35)

Country Link
US (3) US10654850B2 (es)
EP (2) EP4414365A1 (es)
JP (2) JP7474243B2 (es)
KR (2) KR102890905B1 (es)
CN (1) CN112911935A (es)
AU (2) AU2019344928B2 (es)
BR (1) BR112021004926A2 (es)
CA (1) CA3113236A1 (es)
CL (1) CL2021000648A1 (es)
CO (1) CO2021004789A2 (es)
DK (1) DK3852533T3 (es)
EC (1) ECSP21026485A (es)
ES (1) ES2982498T3 (es)
FI (1) FI3852533T3 (es)
HR (1) HRP20240707T1 (es)
HU (1) HUE067188T2 (es)
IL (1) IL281438B2 (es)
LT (1) LT3852533T (es)
MA (1) MA71645A (es)
MD (1) MD3852533T2 (es)
MX (1) MX2021003152A (es)
MY (1) MY208106A (es)
PE (2) PE20211774A1 (es)
PH (1) PH12021550443A1 (es)
PL (1) PL3852533T3 (es)
PT (1) PT3852533T (es)
PY (1) PY1977703A (es)
RS (1) RS65558B1 (es)
SG (1) SG11202102053VA (es)
SI (1) SI3852533T1 (es)
SM (1) SMT202400201T1 (es)
TW (2) TWI828758B (es)
UA (1) UA128841C2 (es)
UY (1) UY38377A (es)
WO (1) WO2020061162A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684364A4 (en) 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
MA71645A (fr) * 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
IL286481B2 (en) * 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
US12576033B2 (en) * 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
TWI782504B (zh) * 2020-05-08 2022-11-01 美商美國禮來大藥廠 (三氟甲基)嘧啶-2-胺化合物
WO2022006278A1 (en) * 2020-07-01 2022-01-06 Angion Biomedica Corp. Reducing fibrosis and treating related diseases, disorders, and conditions
JP7539545B2 (ja) * 2020-07-03 2024-08-23 武漢朗来科技発展有限公司 複素環化合物及びその使用
EP4289846A4 (en) * 2021-02-07 2025-01-22 Wuhan LL Science and Technology Development Co., Ltd. HETEROCYCLIC COMPOUND, AND ITS INTERMEDIATE, PROCESS FOR THEIR PREPARATION AND THEIR USE
US20250122190A1 (en) * 2021-09-10 2025-04-17 Medshine Discovery Inc. Halogen-substituted pyridazinone compound and application thereof
WO2025250920A1 (en) 2024-05-31 2025-12-04 Gfb (Abc), Llc Pyridazinone phosphate compounds, pharmaceutical compositions, and medical uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77526C2 (en) 2002-06-07 2006-12-15 Sanofi Aventis Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy
CA2553969A1 (en) * 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN101124217A (zh) 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
DE102004044231A1 (de) 2004-09-14 2006-03-16 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
BRPI0517418A (pt) 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
MX2009009849A (es) 2007-03-15 2009-09-24 Schering Corp Derivados de piridazinona sustituida con piperazina utiles como inhibidores de glucano sintasa.
WO2009057827A1 (en) * 2007-10-31 2009-05-07 Nissan Chemical Industries, Ltd. Pyridazinone derivatives and use thereof as p2x7 receptor inhibitors
US8633233B2 (en) * 2008-08-06 2014-01-21 Hydra Biosciences, Inc. Methods and compositions for treating anxiety
US8975260B2 (en) * 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
AU2012382373A1 (en) * 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
WO2016023830A1 (en) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione derivatives
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
MA71645A (fr) 2018-09-18 2025-05-30 Goldfinch Bio, Inc. Pyridazinones et leurs procédés d'utilisation
IL286481B2 (en) * 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
WO2020206623A1 (en) * 2019-04-10 2020-10-15 Goldfinch Bio, Inc. Crystal forms
US12576033B2 (en) * 2019-04-11 2026-03-17 Gfb (Abc), Llc Spray-dried formulation of a pyridazinone TRPC5 inhibitor
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置

Also Published As

Publication number Publication date
US20220024917A1 (en) 2022-01-27
JP2024099595A (ja) 2024-07-25
EP4414365A1 (en) 2024-08-14
TW202430524A (zh) 2024-08-01
EP3852533B1 (en) 2024-02-28
ES2982498T3 (es) 2024-10-16
KR20210069652A (ko) 2021-06-11
RS65558B1 (sr) 2024-06-28
TW202035402A (zh) 2020-10-01
UY38377A (es) 2020-04-30
KR102890905B1 (ko) 2025-11-24
HRP20240707T1 (hr) 2024-10-11
BR112021004926A2 (pt) 2021-06-01
IL281438B2 (en) 2023-12-01
PE20211774A1 (es) 2021-09-08
EP3852533A4 (en) 2022-06-15
MY208106A (en) 2025-04-15
ECSP21026485A (es) 2021-07-30
HUE067188T2 (hu) 2024-10-28
CA3113236A1 (en) 2020-03-26
KR20250171415A (ko) 2025-12-08
FI3852533T3 (fi) 2024-05-24
PH12021550443A1 (en) 2021-12-06
JP2022500359A (ja) 2022-01-04
MA71645A (fr) 2025-05-30
WO2020061162A1 (en) 2020-03-26
SI3852533T1 (sl) 2024-10-30
CO2021004789A2 (es) 2021-07-30
CL2021000648A1 (es) 2021-08-06
TWI828758B (zh) 2024-01-11
IL281438A (en) 2021-04-29
US11046690B2 (en) 2021-06-29
PL3852533T3 (pl) 2024-09-16
US20200102301A1 (en) 2020-04-02
AU2019344928B2 (en) 2025-07-03
AU2019344928A1 (en) 2021-04-29
MX2021003152A (es) 2021-06-23
UA128841C2 (uk) 2024-11-06
US10654850B2 (en) 2020-05-19
EP3852533A1 (en) 2021-07-28
LT3852533T (lt) 2024-06-10
JP7474243B2 (ja) 2024-04-24
AU2025238155A1 (en) 2025-10-23
DK3852533T3 (da) 2024-05-27
CN112911935A (zh) 2021-06-04
MD3852533T2 (ro) 2024-08-31
SMT202400201T1 (it) 2024-07-09
US20200283437A1 (en) 2020-09-10
PY1977703A (es) 2020-06-19
TWI894724B (zh) 2025-08-21
PT3852533T (pt) 2024-05-31
IL281438B1 (en) 2023-08-01
SG11202102053VA (en) 2021-04-29
EP3852533B8 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
PE20250453A1 (es) Piridazinonas y sus metodos de uso
CO2021017981A2 (es) Inhibidores heterobicíclicos de mat2a y métodos de uso para el tratamiento del cáncer
CL2021001721A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso para tratar el cáncer
CL2021001722A1 (es) Inhibidores aza-heterobicíclicos de mat2a y métodos de uso en el tratamiento de cáncer
FI3727426T3 (fi) Inkretiinianalogeja ja niiden käyttötarkoituksia
MX2020008754A (es) Compuestos farmaceuticos.
UY38296A (es) Derivados de 3–(5–amino–1–oxoisoindolin–2–il)piperidin–2,6–diona y sus usos
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
GEP20227453B (en) Glp-1 receptor agonists and uses thereof
EA201992327A1 (ru) Пептид, активирующий рецептор гип
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
MX2021008094A (es) Metodos y composiciones para el tratamiento del cancer.
PE20180571A1 (es) Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
CO2017001919A2 (es) Anticuerpos anti-her2 e inmunoconjugados
AR107154A1 (es) Estimuladores de guanilato ciclasa soluble
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
MX388749B (es) Compuestos de imidazo-piperidina fusionada que contienen una amida heterocíclica de 4 miembros como inhibidores de jak.
MX386981B (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
CO7111284A2 (es) Nucleósidos de espirooxetano de uracilo
CL2016002033A1 (es) Compuestos derivados de benzimidazol-2 amino con actividad inhibidora (midh1 r132h); composición farmacéutica, procedimiento de preparación; uso en el tratamiento de tumores gastrointestinales, tumor endocrino, síndrome mielodisplásico, leucemia, tumor de mamas, , metástasis, entre otros.
UY32622A (es) Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
MX2020011845A (es) Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer